Echocardiographic Assessment of TR Etiology: Implications for Therapy Selection

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Consultant Fee/Honoraria/Speaker's Bureau - Abbott; Moray Medical; HVR Cardio
• Equity/Stock(s)/Options - ReNiva, Inc